Squarepoint
XENE icon

Squarepoint’s Xenon Pharmaceuticals XENE Stock Holding History

Squarepoint’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$498K Buy
+13,400
New +$796K ﹤0.01% 3384

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Squarepoint's XENE Position: Q3 2026 in Review

Squarepoint reduced its Xenon Pharmaceuticals (XENE) stake by 68% in Q3 2026, selling an estimated $4.57M and leaving 35,953 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2535.

Squarepoint first reported a position in XENE in Q1 2019 and has held it in 14 quarters since. The position peaked at $6.81M in Q2 2026. 156 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • Squarepoint held 35,953 shares of Xenon Pharmaceuticals worth $1.34M as of Q3 2026.
  • Squarepoint sold 76,916 Xenon Pharmaceuticals shares in Q3 2026, an estimated $4.57M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #2535 holding.
  • Squarepoint first reported a position in Xenon Pharmaceuticals in Q1 2019 and has held it in 14 quarters since.
  • Squarepoint's Xenon Pharmaceuticals position peaked at $6.81M in Q2 2026.
  • 156 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.